Equity Overview
Price & Market Data
Price: $2.79
Daily Change: +$0.12 / 4.30%
Daily Range: $2.73 - $2.90
Market Cap: $198,606,848
Daily Volume: 149,613
Performance Metrics
1 Week: 20.09%
1 Month: 13.31%
3 Months: 57.87%
6 Months: 76.73%
1 Year: 170.2%
YTD: 108.2%
Company Details
Employees: 106
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.